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Abstract
Background: Cardiovascular disease is prevalent in children on dialysis and accounts for almost 30% of all deaths.
Randomised trials in adults suggest that haemodiafiltration (HDF) with high convection volumes is associated with
reduced cardiovascular mortality compared to high-flux haemodialysis (HD); however paediatric data are scarce. We
designed the haemodiafiltration, heart and height (3H) study to test the hypothesis that children on HDF have an
improved cardiovascular risk profile, growth and nutritional status and quality of life, compared to those on
conventional HD.
We performed a non-randomised parallel-arm intervention study within the International Paediatric Haemodialysis
Network Registry comparing children on HDF and conventional HD to determine annualised change in cardiovascular
end-points and growth. Here we present the 3H study design and baseline characteristics of the study population.
Methods: 190 children were screened and 177 (106 on HD and 71 on HDF) recruited from 28 centres in 10 countries.
There was no difference in age, underlying diagnosis, comorbidities, previous dialysis therapy, dialysis vintage, residual
renal function, type of vascular access or blood flow between HD and HDF groups. High flux dialysers were used in 63%
of HD patients and ultra-pure water was available in 52%. HDF patients achieved a median convection volume of 13.3
L/m2; this was associated with the blood flow rate only ((p = 0.0004, r = 0.42) and independent of access type (p = 0.38).
Discussion: This is the largest study on dialysis outcomes in children that involves deep phenotyping across a wide
range of cardiovascular, anthropometric, nutritional and health-related quality of life measures, to test the hypothesis
that HDF leads to improved cardiovascular and growth outcomes compared to conventional HD.
Trial registration: ClinicalTrials.gov: NCT02063776. The trial was prospectively registered on the 14 Feb 2014.
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Background
Cardiovascular disease is the most common cause of mor-
tality in children and young adults on dialysis, accounting
for 30% of deaths [1]. Chronic fluid overload and mineral
dysregulation with hyperphosphataemia and hyperpara-
thyroidism, are widely prevalent in dialysis patients. While
cardiovascular morbidity begins in pre-dialysis chronic
kidney disease (CKD), it is accelerated on dialysis [2, 3], as
mineral bone disease, fluid overload and factors specific to
the dialysis milieu are accentuated with longer dialysis
vintage [4, 5]. Even within a short period of 3 months on
conventional haemodialysis (HD), biomarkers of inflam-
mation, oxidative stress and endothelial dysfunction were
shown to increase [6].
Outcomes on HD cannot be further improved by in-
creasing the flux or efficiency of dialysis [7]. Haemodia-
filtration (HDF) is a newer technique of dialysis that
utilises a combination of diffusive and convective solute
transport through a highly permeable membrane [8–10],
thereby achieving clearance of middle and large molecu-
lar weight solutes unlike conventional HD. In recent
years randomised trials in adults have shown that HDF
is associated with improved cardiovascular and all-cause
mortality compared to HD [11–13], and a dose-response
relationship has been demonstrated between the magni-
tude of the convection volume and survival [13]. In
addition, ultra-pure dialysate that is used in HDF re-
duces low-grade endotoxaemia, that can develop in HD
patients [14].
HDF is increasingly used in children, but there are few
data on outcomes. Fischbach et al. showed improved nu-
trition and growth [15], reduced inflammation [16], re-
gression of left ventricular hypertrophy [16, 17], improved
anaemia control [16] and reduced post-dialysis recovery
time [15] in a small number of children undergoing daily
HDF. Recent studies from our group have shown that
when HD patients are switched to HDF keeping all other
dialysis related parameters constant, a significant im-
provement in inflammation, antioxidant capacity and
endothelial risk profile was achieved even within a
short time of 3 months on HDF [6], however longer
term effect on cardiovascular outcomes is unknown.
There are no prospective studies comparing the out-
comes of HD with HDF in children.
We designed the haemodiafiltration, heart and height
(3H) study to test the hypothesis that children on HDF
have an improved cardiovascular risk profile, growth and
nutritional status and quality of life, compared to those on
conventional HD. The 3H study will investigate the extent
and progression of cardiovascular morbidity using a broad
spectrum of measures in the largest cohort of children
and adolescents on dialysis assembled to date. These data
will allow us to determine the optimal dialysis modality
for children requiring in-centre dialysis, the modifiable
risk factors for improving cardiovascular and nutritional
outcomes as well as important patient related outcome
measures (PROMs).
Methods
The 3H study will systematically evaluate cardiovascular,
nutritional and health-related quality of life (QoL) mea-
sures in children on HD and HDF to test the hypothesis
that children on HDF have an improved cardiovascular
risk profile and growth and nutritional status compared
to those on conventional HD. Primary and secondary
outcome measures are described in Table 1. We will as-
sess for difference in these outcomes between the two
dialysis modalities, and the impact of modifiable risk fac-
tors, including clinical and dialysis-related factors, bio-
chemical measures and medications. PROMs will be
assessed using established QoL questionnaires as well as
dialysis-specific outcomes. This is a registered clinical
trial (ClinicalTrials.gov: NCT02063776).
Study design
3H is a multi-centre, non-randomised parallel-arm inter-
vention study carried out by investigators of the Inter-
national Paediatric Hemodialysis Network (IPHN)
Registry and the Cardiovascular Comorbidity in Child-
hood CKD (4C) Study [18]. The IPHN prospectively col-
lects detailed data from children on maintenance
haemodialysis via an on-line electronic system (www.pedp-
d.org). The infrastructure, expertise and collaborations of
the 4C study consortium, that is performing longitudinal
follow-up in a cohort of over 700 children with CKD, is uti-
lised and expanded for clinical and cardiovascular monitor-
ing in 3H.
Children were recruited from 28 paediatric dialysis
units across Europe and in Toronto, Canada. A mini-
mum follow-up of 12 months was required.
Inclusion criteria
1. Paediatric patients, 5–20 years of age undergoing
post-dilution HDF or HD (incident and prevalent
patients)
2. HD or HDF for 4 h per session 3 times per week
3. A single pool Kt/V > 1.2 in prevalent patients in the
month preceding recruitment
Exclusion criteria
1. Children in whom a living donor kidney transplant
is planned within 6 months
2. Pre-dilution HDF
3. HD or HDF of any duration other than 4 h per
session 3 times per week
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Primary end points
1. Annualised change in carotid intima media thickness
(cIMT) standard deviation score (SDS).
2. Annualised change in height SDS.
Secondary end-points
Secondary end-points related to cardiovascular mea-
sures, nutrition and growth, and QoL are listed in
Table 1.
HDF and HD procedures
Standardised procedures for HDF and HD were provided
to all centres, but individualised changes to the dialysis
prescription will be left to the treating physician. The
decision to perform HD or HDF were left to the treating
physicians in each centre. In order to determine the ef-
fect of convective clearance on outcome, only prevalent
HD patients with single pool Kt/V > 1.2 in the preceding
month were enrolled. Given that recent RCTs in adults
have shown that all cause and cardiovascular mortality
are lower when higher convection volumes are used
[13], we will aim for a comparable target convection vol-
ume of 12-15 L/m2 body surface area in children. Ultra-
pure dialysis fluid (defined as containing < 0.1
colony-forming unit/ml (CFU/ml) and < 0.03 endotoxin
unit/ml (EU/ml)) will be used as per international stan-
dards and depending on availability in each unit. HD will
be performed with similar membranes using a similar
blood flow rate and dialysate composition as on HDF.
Pure (defined as containing < 100 CFU/ml and < 0.25
EU/ml) or ultrapure dialysate will be used. One- to
3-monthly assessments of water quality will be per-
formed in each centre as per local protocols, and in
addition, water quality at each centre will be checked in
a central lab annually. The choice of dialysate sodium,
bicarbonate and calcium, as well as sodium or ultrafiltra-
tion profiling, will be left to physician discretion, but
noted in all cases.
Study organization
Patients meeting the inclusion criteria will be enrolled by
local investigators. Six investigators serve as regional coor-
dinators and visit study centres annually to perform the
vascular scans, collect blood samples and complete data
entry. All investigators will be provided with portable
equipment for imaging. To ensure optimal reproducibility
and quality of the imaging, prior to the start of the study
the coordinators will be trained in all the vascular im-
aging, and blinded assessment of the vascular measures
will be performed periodically to determine intra-observer
and inter-observer variability. All training of the in-
vestigators was performed as part of the 4C study
[19], and 6-monthly investigator meetings will be held
alongside the 4C study meetings to synchronize study
Table 1 Summary of data to be obtained in the 3H study
Cardiovascular measures (annual
intervals)
(i) High resolution sonography of the common carotid arteries to measure intima media thickness
(morphology, B-Mode) and elasticity (function, M-mode)
(ii) Pulse wave velocity and augmentation index
(iii) Echocardiogram
(iv) 24-h ambulatory blood pressure monitoring
Anthropometry
-6-monthly intervals- (i) Weight, height, body mass index and pubertal staging
(ii) Body composition analysis by multifrequency bioelectrical impedance analysis
Biomarker monitoring (6-monthly intervals)
-Nutritional measures Albumin, prealbumin, leptin, ghrelin, cholecystokinin, endogenous growth hormone production (IGF-1, IGF-
binding protein), adiponectin, resting energy expenditure (calculated), normalized protein catabolic rate
(calculated), physical activity index
-Cardiovascular measures calcium, phosphate, parathyroid hormone, FGF-23 (c-terminal), soluble klotho, 25-hydroxyvitamin D,
1,25-dihydroxyvitamin D, β2 microglobulin, fetuin-A, osteoprotegerin, markers of inflammation (IL6, IL-10,
high-sensitivity CRP, TNF-α, plasma intradialytic endotoxin), markers of endothelial dysfunction (homocysteine,
ADMA, SDMA), markers of bone turnover (bone-specific alkaline phosphatase, sclerostin, collagen telopeptides,
β-cross-laps), markers of oxidative and carbonyl stress
Quality of life questionnaires (6-
monthly intervals)
(i) Paediatric Index of Emotional Distress (Pi-ED)
(ii) Paediatric Quality of Life (PedsQL)
(iii) Strengths Difficulties Questionnaire (SDQ)
(iv) Patient related outcome measures related to dialysis: post-dialysis recovery time, sleep pattern, school
attendance, physical activity, appetite.
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activities, discuss results, and exchange experiences.
In the only non-European centre, Toronto, the local
radiologists will perform the vascular imaging as per
study protocol, and all the scans will be analysed cen-
trally. Standard operating procedures for IMT, PWV,
ECHO and ABPM are available on the IPHN website
for easy reference.
Investigational plan
The following investigations will be performed as out-
lined in Table 1. All investigations will be performed be-
fore a mid-week session of dialysis and completed within
a 2 week interval of each other.
I - cardiovascular monitoring (baseline and annual
intervals)
1. cIMT - High resolution ultrasound of the common
carotid artery to measure cIMT (morphology, B-
Mode) and elasticity (function, M-Mode) according
to the Mannheim cIMT consensus [20]. The cIMT
will be obtained by five averaged measurements
on each side using a portable ultrasound device
(Acuson P50; Siemens Medical Solutions USA, Inc.)
with integrated digital image evaluation software
(Syngo US Workplace; Siemens Medical Solutions
USA, Inc.). As cIMT in children changes with
growth, it will be expressed as a SDS using reference
values normalized for age, sex and height derived
from healthy children [21].
2. Aortic pulse wave velocity (PWV) and augmentation
index will be measured with the Oscillometric
Vicorder device using the distance from the
suprasternal notch to the femoral recording point via
the umbilicus as path length. The method was
validated against the gold standard of applanation
tomonetry [22], and PWV SDS values normalized for
age, sex and height were derived from a large
European paediatric population [22].
3. Two–dimensional echocardiography (ECHO)
images are obtained for the analysis of left
ventricular (LV) volume, wall thickness and
chamber dimensions. The LV mass will be
calculated according to the Devereux Equation [23]
and indexed to height (LVMI) and sex– and age–
specific LVMI partition values of Khoury et al. [24]
applied to define left ventricular hypertrophy
(LVH). Echocardiographic assessments will be
performed either by a local cardiologist or by the
regional coordinator, standardized according to the
guidelines of the American Society of
Echocardiography [25].
4. 24-h ambulatory blood pressure monitoring
(ABPM) will be performed using the Spacelab
ABPM portable device (Spacelabs 90,207–2Q) as
previously described [26]. The time–averaged 24-h
mean arterial pressure (MAP) will be used for the
analyses and hypertension defined as 24-h time–in-
tegrated MAP exceeding the 95th percentile [26].
Patients on antihypertensive medications will be
referred to as having controlled or uncontrolled
hypertension if their 24-h MAP is below or above
the 95th percentile, respectively.
5. Bioimpedence spectroscopy will be performed using
the Fresenius body composition monitoring (BCM®;
Fresenius Medical Care, GmbH) device as
previously described [27]. This multi-frequency
bioimpedance analysis measures 50 frequencies
between 5 to 1000 kHz and calculates the extracel-
lular, intracellular and total body water. Parameters
generated directly from the device namely absolute
overhydration (OH, litre) and relative overhydration
(Rel-OH; %) will be recorded. Using standardised
definitions, overhydration is defined as Rel-OH
≥7% and severe overhydration when Rel-OH
is ≥15% [28].
II - clinical and anthropometric data (baseline and
6-monthly intervals)
Height, weight, body mass index, waist-hip circumfer-
ence and pubertal stage will be measured using standard
techniques [29]. The height velocity will be calculated as
the change in height over a 6-month period standardised
for age.
III - biochemical and biomarker monitoring: (baseline and
6-monthly intervals)
Blood samples will be collected before a mid-week ses-
sion of dialysis, centrifuged and stored at -80 °C in the
local hospitals before shipping to a central biorepository.
Analyses will be performed on batched samples in a cen-
tral lab.
IV - health-related quality of life questionnaire (baseline
and 6-monthly intervals)
Three validated information and screening questionnaires
will be given to children and their parents in their local
languages: the paediatric index of emotional distress
(Pi-ED) screens for emotional distress (depression and
anxiety), Paediatric Quality of Life (PedsQL) for health im-
pacts on quality of life and the Strengths Difficulties Ques-
tionnaire (SDQ) for emotional well-being and pro-social
relationships. In addition, information on post-dialysis re-
covery time, physical activity, school or college attendance
and sleep pattern will be recorded by the patient. All ques-
tionnaires will be analysed by a single psychologist blinded
to the clinical status of the child.
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Data acquisition and handling
Data will be collected in the IPHN Registry by on-line
data entry by the local physicians assisted by the regional
investigators. All patient-specific data will be pseudony-
mized at the local study centres and the website and
database will be on a secure server containing a
password-protected domain. Study performance will be
reviewed annually by a data monitoring committee.
Statistical analysis
All analyses has been decided a priori in an analysis
plan. Each quantitative outcome will be assessed for nor-
mality. cIMT, PWV, 24-h MAP profiles and height will
be expressed in SD scores. The co-primary endpoints of
mean and standard deviation (or median/interquartile
range if appropriate) annualised change between baseline
and 1 year in cIMT and height SDS will be calculated,
and compared between the HDF and HD cohorts using
unpaired t-tests (or the non-parametric equivalent). As
the data are observational, adjustment for potential con-
founders (country, age, gender, access type, dialysis vin-
tage) will be made using linear regression. The
adjustment for the primary analysis will be made
through the construction of propensity scores, repre-
senting the likelihood of receipt of HDF (vs HD), based
on the pre-specified confounders. A sensitivity analysis
will be performed to ensure robustness of results, adjust-
ing for potential confounders through a multivariable
linear regression model. The annual change in secondary
endpoints will be investigated similarly, but these ana-
lyses are not formally powered, and so will be considered
as secondary analyses. Correlations between continuous
variables will be made using Pearson correlation coeffi-
cients if variables are normally distributed, or Spear-
man’s rank correlation coefficients otherwise.
Both intention to treat (based on the dialysis modality
HD or HDF at the start of the study) and per protocol
(at least 90% of all dialysis sessions must be in the
assigned group) analyses will be performed. All analyses
will be performed in SAS Version 9.4 (SAS Institute Inc.,
Cary, NC). All statistical tests will be two sided and
p-values of < 0.05 will be nominally considered to indi-
cate a statistically significant difference between groups.
Sample size
In a parallel study investigating cardiovascular disease
progression in children on HD we have shown a mean
(SD) increase in cIMT by 0.5 ± 0.3 SDS/year compared
to 0.0 ± 0.6 SDS/year in pre-dialysis CKD patients (un-
published data). Making a conservative assumption of an
average annualized change of 0.4 ± 0.5 SDS in HD vs 0.1
± 0.5 SDS in the (presumably) more stable HDF group,
69 children per group were required at 90% power and
2.5% Type I error (resulting in a 5% overall Type I error
for the two primary endpoints; Bonferroni correction).
Accounting for a 10% dropout rate, 76 subjects per
group are needed. No paediatric longitudinal data are
available regarding changes in height SDS or functional
parameters such as PWV, and so no formal power calcu-
lation can be performed. On interim analysis at 1-year a
significantly higher drop-out rate (due to transplant-
ation) was noted in the HDF compared to the HD group.
Hence, with permission from the Institutional Review
Board, we extended the recruitment period by a further
12 months, and 5 new centres joined the study.
Ethical aspects
The study was performed according to the principles of
the declaration of Helsinki. The patient information and
consent forms (translated into the national languages)
were reviewed and approved by the local Institutional
Review Boards in each participating centre. Appropriate
measures were used to guarantee maximal data confi-
dentiality. All patient-related clinical data, including vas-
cular scans and blood samples, was pseudonymized
locally. Neither the laboratories nor the central office
were able to identify individual patients, and no investi-
gator other than the local physicians at each site were
able to correlate results with clinical or laboratory data
or vascular imaging.
Baseline characteristics
One hundred ninety children were recruited from 28
centres in 10 countries (Turkey 48, United Kingdom
40, France 22, Italy 20, Germany 19, Greece 16, Serbia
8, Poland 7, Canada 8 and Czech Republic 2). Thirteen
children did not meet the inclusion criteria and were
excluded from further analysis (age < 5 years in 1, dia-
lysis frequency or duration not 4 h 3 times per week
in 7, pre-dilution HDF in 2, ultrapure water not used
for HDF in 2 and transplantation on the day of the
study in 1).
Baseline characteristics of the 177 children (106 on
HD and 71 on HDF) who entered the study are de-
scribed in Table 2. There was a higher prevalence of girls
on HDF, but no difference was seen in age, ethnicity,
underlying renal disease or presence of comorbidities.
The number of children with residual urine output were
similar between HD and HDF groups.
Details of dialysis therapy
Dialysis related parameters in the HD and HDF groups
are described in Table 2. Ultra-pure dialysate was used
for all HDF patients but less consistently in HD patients,
(n = 71, 100% vs n = 55, 52%; p < 0.0001). High-flux
dialysers were used in 67 (63%) of HD patients. There
was no difference in the dialysate sodium, calcium or
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Table 2 Demographics of the study population at baseline
Haemodialysis n (%) or Median (IQR) Haemodiafiltration n (%) or Median (IQR) p
Number 106 71
Age
5–10 22 (20.8) 15 (21) 0.78
10–15 37 (34.9) 27 (38)
15–20 47 (44.3) 29 (41)
Gender (female) 45 (42) 43 (60) 0.03
Ethnicity
Caucasian / Asian / African /other 66 / 21 / 9 /’10 46 / 17 / 5 / 3 0.42
Underlying renal diagnosis
Dysplasia 54 (51) 32 (45) 0.76
Glomerulonephritis 25 (24) 19 (26)
Cystic kidney disease 4 (4) 5 (7)
Other 17 (15) 11 (16)
Unknown 6 (6) 4 (6)
Presence of comorbidities 0.81
Impaired cognitive development 22 (21) 14 (20)
Impaired motor development 11 (10) 6 (8)
Ocular or hearing abnormalities 18 (17) 11 (15)
Other abnormalities 25 (24) 13 (18)
Confirmed genetic disorder 17 (16) 12 (17)
Previous dialysis 35 (33) 34 (48) 0.07
Modality (PD / HD / both) 22 / 8 / 5 14 / 14 / 6 0.17
Cumulative time on dialysis before study (months) 24 (10, 52) 28 (16, 45) 0.92
Previous transplant 18 (17) 21 (29) 0.06
Time with functioning graft (mts) 33 (16, 96) 66 (12, 114) 0.96
Residual urine volume (ml/day)
< 200 / 200–500 / > 500 66 (62) / 22 (21) / 18 (17) 44 (62) / 13 (18) / 14(20) 0.85
Details of dialysis therapy
Filter
High flux / Mid flux / Low flux 67 (63) / 24 (23) / 15(14) 71 (100) < 0.00001
Dialysis water qualitya
Pure vs ultrapure 51 (48) / 55 (52) 71 (100) < 0.00001
Vascular accessb
AVF / CVL / AVG 34 (33) / 71 (67) / 1 (1) 27 (38) / 42 (59) / 2(3) 0.34
Blood flow /m2 body surface area 182 (148, 215) 174 (144, 205) 0.40
Dialysate sodium
≤ 138 mmol/l 76 (72) 49 (69) 0.79
> 138 mmol/l 30 (28) 22 (31)
Dialysate bicarbonate
32–35 mMol/L 68 (64) 42 (59) 0.48
36–42 mMol/L 38 (36) 29 (41)
IQR – interquartile range; aDialysate water quality: Pure dialysis fluid is defined as containing < 100 colony-forming unit/ml (CFU/ml) and < 0.25 endotoxin unit/ml
(EU/ml). Ultrapure dialysis fluid is defined as containing < 0.1 CFU/ml and < 0.03 EU/ml; bVascular access: AVF – arteriovenous fistula; CVL – central venous line;
AVG – arteriovenous graft
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bicarbonate concentration between groups. The distribu-
tion of vascular access types (CVL, AVF and AVG) was
comparable between the groups.
The median blood flow rate (standardised to body sur-
face area) was similar between HD and HDF groups (182
[148–215] vs 174 [144–205] L/m2; p = 0.4) and was inde-
pendent of the type of vascular access (p = 0.09; Fig. 1a).
The median convection volume achieved in the HDF
group was 13.3 (IQR 11.5 to 14.2) L/m2. The convention
volume showed a strong linear relation with the blood
flow rate (p = 0.0004, r = 0.42; Fig. 2), but was independent
of the type of vascular access (p = 0.38; Fig. 1b), age or
gender.
Discussion
The 3H study is a multi-centre prospective clinical trial
testing the hypothesis that HDF improves cardiovascular,
nutritional and health-related QoL outcomes compared
to conventional HD in children.
Conventional HD is based on diffusive transport alone
and cannot remove middle-molecular-weight solutes effi-
ciently even with the use of high-flux membranes. Middle-
molecular-weight uraemic toxins include β2-microglobulin,
adiponectin, leptin, ghrelin, cholecystokinin and many
others hormones and inflammatory cytokines [30].
Middle-molecular-weight toxins mediate inflammation,
oxidative stress, endothelial dysfunction and cardiovascular
disease and have been associated with increased mortality
in adults on dialysis [31]. As the importance of uraemic
toxins is recognized, the need for alternative therapies that
provide better removal of those solutes has become evident.
HDF is a blood purification therapy combining diffusive
and convective solute transport using high-flux membrane
[14]. Convective transport is achieved by an effective con-
vection volume of at least 20% of the total blood volume
processed which is replaced by infusion of a sterile,
non-pyrogenic solution [14].
Middle and large molecular weight compounds such
as β2-microglobulins that normally accumulate on HD
have > 70% better removal on HDF [32, 33]. Plasma
phosphate has a 30% greater clearance by HDF [34]. The
use of ‘ultrapure’ dialysate and increased removal of in-
flammatory cytokines [35] reduces inflammation and
oxidative stress. Erythropoietin sensitivity is improved,
possibly as a result of reduced inflammation and re-
moval of erythropoiesis-inhibiting factors [34]. In HDF
cooling of the patient occurs because of the large volumes
of fluid that are infused, reducing the incidence of intradia-
lytic hypotension, improving intradialytic hemodynamic
stability [36], allowing faster recovery time post-dialysis,
and explaining, in part, the improved cardiovascular out-
comes [37].
Several prospective observational studies in adults
have shown that HDF reduces cardiovascular and
all-cause mortality, and recently the results of three large
RCTs, collectively encompassing more than 2400 adults
on dialysis, were published. Neither the CONvective
TRAnsport STudy (CONTRAST) [38], nor the Turkish
HDF study [12] showed a priori that there was any sig-
nificant difference in all-cause mortality or cardiovascu-
lar events (both fatal and non-fatal) between HDF and
HD. However, the Estudio de Supervivencia de Hemo-
diafiltracion On-Line (ESHOL), the RCT with the high-
est achieved convection volumes, reported superiority of
HDF over HD with respect to all-cause and cardiovascu-
lar mortality [11]. Notably, post hoc analyses of all three
Fig. 1 a Blood flow, expressed as litres/m2 body surface area, in children on HD and HDF with central venous lines (CVLs), arteriovenous fistulae
(AVFs) and arteriovenous grafts (AVGs). b The relationship between blood flow and convection volume in children on HDF with CVLs, AVFs and
AVGs. Convection volume is independent of the type of vascular access
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studies suggested a dose-effect relationship between con-
vection volume and mortality risk, even after adjustment
for potential confounders [11, 12, 38]. Since data from
the RCTs is inconsistent, a pooled individual participant
data analysis of RCTs showed that HDF reduces the risk
of mortality compared with conventional HD [13]. The
mechanisms for improved survival are not clear, and it is
not known if equivalent benefits can be expected in chil-
dren on HDF.
HDF has been performed in children since the
mid-70s, and is shown to be a safe and well tolerated
treatment [16]. However, there are few children on
HDF across the world. According to a survey of 51
paediatric dialysis units across Europe HDF is prac-
ticed only in 24 (47%) centres, with 12% of all chil-
dren on extracorporeal dialysis receiving HDF [39]. In
order to meet the numbers required in each arm of
the study a multinational approach, involving as many
centres that perform HDF as possible, was required.
We utilised and extended the infrastructure developed
in the ongoing 4C study [18], extending the catch-
ment area to include other countries and centres too.
However, due to small numbers we had to include
both incident and prevalent dialysis patients. Random-
isation was not possible as many centres were not
willing to switch HDF patients back to HD, largely
due to patient preference. Instead, a clinical trial
within the IPHN registry was performed, and propen-
sity matching analysis will be undertaken to adjust for
centre bias. Although a rigorous study design was de-
veloped, not all dialysis centres were able to use
high-flux dialysers or ultra-pure water; effects of dia-
lysis membrane and dialysate purity will be examined
by multivariable analysis. Given that children may
switch between HD and HDF, both intention-to-treat
and ‘as-treated’ analyses will be performed, ensuring
that each patient has received at least 90% of their
dialysis treatment in the assigned modality.
The convection volume is one of the key parameters of
HDF prescription and outcomes as shown in the pooled
study [13]. In the 3H study we were able to achieve me-
dian convection volumes of 13.4 L/m2 in children, which
is comparable to the 23 L per 1.73 m2 per session that
proved beneficial in the pooled study. Importantly, the
convection volume was independent of patient related fac-
tors such as age, gender, access type or dialyser used, but
strongly correlated with the blood flow rate, implying that
convection volume is a modifiable factor that can be ma-
nipulated and optimised by the dialysis team.
As with all paediatric studies, hard end-points are for-
tunately rare, and surrogate measures of early cardiovas-
cular disease have been used. Our primary end-point,
change in cIMT, is a well-established surrogate measure
of the extent of coronary artery disease, correlating with
coronary angiography and intravascular ultrasound re-
sults [40]. It has been correlated with hard endpoints
such as myocardial infarction and stroke in adults with-
out CKD [41] and cardiovascular events in CKD [42]
and dialysis [43] patients. Similarly, increased PWV has
been associated with higher mortality rates even in
young adults on dialysis [44].
The 3H study will also examine factors related to
growth and nutrition and their association with dialysis
modality, if any. Despite major advances in the under-
standing and therapy of uraemic growth failure, 35 to
50% of children with end-stage kidney disease still grow
up to become small adults with a final height below the
third percentile of the general population [45]. In a pre-
vious study in children, HDF was associated with im-
pressive catch-up growth achieving a normal height, at
or above their target mid-parental height [15]. However,
this small single centre study utilised 6 days per week
HDF in the pre-dilutional mode, where the replacement
fluid is infused upstream of the dialyser, allowing higher
filtration rates than are possible than with post-dilution
HDF. Daily HDF improved appetite and corrected meta-
bolic acidosis, but other hypothetical mechanisms for
improved growth may also include reduced inflamma-
tory cytokine release improving target tissue sensitivity
to growth hormone, and superior removal of accumu-
lated endogenous somatomedin and gonadotropin inhib-
itors, leading to an overall anabolic state [46]. The effect
of thrice-weekly post-dilutional HDF on growth has not
been studied; the 3H study will address growth out-
comes, and also investigate biomarkers of nutritional
and growth in HD and HDF patients.
Taken together, the 3H study is the largest prospective
study in children on dialysis to date. It includes deep phe-
notyping across a range of cardiovascular, anthropometric,
Fig. 2 Convection volume showed a linear association with blood
flow, expressed as litres/m2 body surface area
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nutritional and health-related QoL measures in a quest to
find modifiable risk factors that are associated with im-
proved outcomes in dialyzed children. If HDF does im-
prove outcomes in children, as it is shown to do in adults,
dialysis physicians and commissioners would need to
consider the widespread adoption of HDF therapy for
children.
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